Video Experimental Relacionado
Updated: Jul 9, 2026
03:37
Evaluating the Effects of Different Polishing Methods on Color Stability of Dental Restorations in Pediatric Dentistry
Published on: June 6, 2025
Una sola dosis de ciprofloxacina versus 12 dosis de eritromicina para el cólera infantil: un ensayo controlado
Debasish Saha1, Wasif A Khan, Mohammad M Karim
1ICDDR, B, Centre for Health and Population Research, Dhaka, Bangladesh. dsaha@icddrb.org
Lancet (London, England)
|September 27, 2005
Resumen
La dosis única de ciprofloxacina ofrece tasas de curación clínica similares para el cólera infantil grave en comparación con la eritromicina. Sin embargo, la ciprofloxacina fue menos efectiva en la erradicación de la bacteria Vibrio cholerae de las muestras de heces.
Área de la Ciencia:
- Enfermedades Infecciosas Pediátricas
- La terapia antimicrobiana es una terapia antimicrobiana.
- Gastroenterología y Gastroenterología.
Sus antecedentes:
- El cólera severo en niños requiere un tratamiento eficaz.
- La ciprofloxacina es una posible opción de dosis única para el tratamiento del cólera.
Objetivo del estudio:
- Para comparar la eficacia de la dosis única de ciprofloxacina frente a la dosis múltiple de eritromicina para el tratamiento del cólera severo en niños.
- Para evaluar las tasas de curación clínica y la erradicación bacteriana.
Principales métodos:
- Un ensayo aleatorizado abierto que involucró a niños de 2 a 15 años con cólera grave.
- Los participantes recibieron una dosis única de ciprofloxacina o 12 dosis de eritromicina durante 3 días.
- El éxito clínico se definió como el cese de las heces acuosas dentro de las 48 horas.
Principales resultados:
- Las tasas de éxito clínico fueron similares: 60% para la ciprofloxacina y 55% para la eritromicina.
- El grupo de ciprofloxacina experimentó menos vómitos, menos heces y un volumen de heces reducido.
- La insuficiencia bacteriológica fue significativamente mayor con ciprofloxacina (58%) en comparación con la eritromicina (30%).
Conclusiones:
- La dosis única de ciprofloxacina proporciona resultados clínicos comparables a las dosis múltiples de eritromicina para el cólera infantil.
- La eritromicina demostró una eficacia superior en la erradicación del Vibrio cholerae.
- Es posible que se necesiten más investigaciones para optimizar el uso de ciprofloxacina o explorar alternativas para el aclaramiento bacteriano.
Videos de Conceptos Relacionados
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...